Brokerages Anticipate Arcus Biosciences, Inc. (NYSE:RCUS) Will Announce Quarterly Sales of $163.47 Million

Wall Street analysts expect Arcus Biosciences, Inc. (NYSE:RCUSGet Rating) to post $163.47 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Arcus Biosciences’ earnings. The highest sales estimate is $444.90 million and the lowest is $22.50 million. Arcus Biosciences reported sales of $9.46 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 1,628%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Arcus Biosciences will report full year sales of $271.83 million for the current financial year, with estimates ranging from $90.00 million to $635.50 million. For the next financial year, analysts anticipate that the firm will post sales of $94.00 million, with estimates ranging from $84.00 million to $108.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Arcus Biosciences.

Arcus Biosciences (NYSE:RCUSGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The company reported $3.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $4.84. Arcus Biosciences had a return on equity of 7.96% and a net margin of 13.80%. The business had revenue of $354.50 million for the quarter, compared to the consensus estimate of $8.87 million.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a report on Friday, April 1st. Zacks Investment Research cut Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 1st. SVB Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a report on Friday, January 7th. Truist Financial raised their target price on Arcus Biosciences from $70.00 to $77.00 in a research report on Friday, February 25th. Finally, The Goldman Sachs Group reduced their price target on Arcus Biosciences from $45.00 to $43.00 in a research report on Thursday, January 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences has a consensus rating of “Buy” and an average target price of $64.43.

In other Arcus Biosciences news, COO Jennifer Jarrett sold 9,617 shares of the business’s stock in a transaction dated Wednesday, March 16th. The shares were sold at an average price of $31.62, for a total value of $304,089.54. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. raised its holdings in Arcus Biosciences by 2.9% during the 3rd quarter. Invesco Ltd. now owns 224,684 shares of the company’s stock worth $7,834,000 after buying an additional 6,331 shares during the period. Franklin Resources Inc. raised its holdings in shares of Arcus Biosciences by 66.4% during the third quarter. Franklin Resources Inc. now owns 1,457,349 shares of the company’s stock valued at $50,818,000 after acquiring an additional 581,311 shares during the period. Granahan Investment Management Inc. MA acquired a new stake in shares of Arcus Biosciences during the third quarter valued at approximately $3,656,000. Credit Suisse AG lifted its position in shares of Arcus Biosciences by 8.1% in the 3rd quarter. Credit Suisse AG now owns 33,055 shares of the company’s stock valued at $1,152,000 after acquiring an additional 2,487 shares in the last quarter. Finally, Sectoral Asset Management Inc boosted its stake in Arcus Biosciences by 9.6% in the 3rd quarter. Sectoral Asset Management Inc now owns 739,010 shares of the company’s stock worth $25,769,000 after purchasing an additional 64,750 shares during the period. Hedge funds and other institutional investors own 63.67% of the company’s stock.

RCUS stock traded up $1.60 during mid-day trading on Friday, reaching $32.35. The company had a trading volume of 3,063 shares, compared to its average volume of 986,762. Arcus Biosciences has a one year low of $22.36 and a one year high of $49.10. The stock has a market capitalization of $2.30 billion, a P/E ratio of 71.51 and a beta of 0.85. The stock’s 50-day simple moving average is $33.09 and its two-hundred day simple moving average is $36.15.

Arcus Biosciences Company Profile (Get Rating)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Featured Stories

Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.